2026-04-27T13:49:46Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/714712024-12-11T10:18:29Zcom_10324_1138com_10324_931com_10324_894col_10324_1226

2024-11-14T13:37:30Z urn:hdl:10324/71471 Human Mesenchymal Stem Cell Secretome Exhibits a Neuroprotective Effect over In Vitro Retinal Photoreceptor Degeneration Usategui Martín, Ricardo Puertas Neyra, Kevin Louis García Gutiérrez, María Teresa Fuentes, Manuel Pastor Jimeno, José Carlos Fernández Bueno, Iván Producción Científica Retinal photoreceptor degeneration occurs frequently in several neurodegenerative retinal diseases such as age-related macular degeneration, retinitis pigmentosa, or genetic retinal diseases related to the photoreceptors. Despite the impact on daily life and the social and economic consequences, there is no cure for these diseases. Considering this, cell-based therapy may be an optimal therapeutic option. This study evaluated the neuroprotective in vitro potential of a secretome of human bone marrow mesenchymal stem cells (MSCs) for retinal pho- toreceptors in vitro. We analyzed the photoreceptor morpho- logic changes and the paracrine factors secreted by human bone marrow MSCs in a physically separated co-culture with degenerated neuroretinas, using organotypic neuroretinal cultures. The results showed that the secretome of human bone marrow MSCs had a neuroprotective effect over the neuroretinal general organization and neuropreserved the photoreceptors from degeneration probably by secretion of neuroprotective proteins. The study of the expression of 1,000 proteins showed increased paracrine factors secreted by MSCs that could be crucial in the neuroprotective effect of the stem cell secretome over in vitro retinal degeneration. The current results reinforce the hypothesis that the paracrine effect of the human bone marrow MSCs may slow photore- ceptor neurodegeneration and be a therapeutic option in retinal photoreceptor degenerative diseases. 2024-11-14T13:37:30Z 2024-11-14T13:37:30Z 2020 info:eu-repo/semantics/article Molecular Therapy - Methods & Clinical Development 2020;17:1155-1166 2329-0501 https://uvadoc.uva.es/handle/10324/71471 10.1016/j.omtm.2020.05.003 1155 1166 Molecular Therapy - Methods & Clinical Development 17 eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ Attribution-NonCommercial-NoDerivatives 4.0 Internacional